The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LPTX | -58.72% | -92.45% | -40.36% | -98% |
| S&P | +12.93% | +85.68% | +13.18% | +196% |
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $18.81M | -80.9% |
| Market Cap / Employee | $0.36M | 0.0% |
| Employees | 52 | -3.7% |
| Net Income | -$3.30M | 81.8% |
| EBITDA | -$3.17M | 82.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.69M | -84.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.04M | -89.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -132.94% | -45.7% |
| Return On Invested Capital | -103.50% | -588.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.32M | 46.7% |
| Operating Free Cash Flow | -$8.32M | 46.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.25 | 0.33 | 0.59 | 3.29 | 120.15% |
| Price to Tangible Book Value | 2.25 | 0.33 | 0.59 | 3.29 | 120.15% |
| Enterprise Value to EBITDA | -4.44 | 1.23 | 0.45 | -2.90 | 18.96% |
| Return on Equity | -141.9% | -202.8% | -183.7% | -196.8% | 84.24% |
| Total Debt | $0.27M | $0.52M | $0.28M | $0.04M | -89.89% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
